Home – Technologies – ProTECT™
Tumor-specific immune co-stimulation in a single, transferable, conditionally active design
With PROgrammed Tumor Engagement and Checkpoint/Co‑stimulation Targeting, our ProTECT™ technology delivers multifunctional tumor-specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory pair such as PD-1/PD-L1.
Therapeutics utilizing ProTECT™ have limited exposure and activity in normal healthy tissue, avoiding on-target, off-tumor toxicities. Once in the tumor microenvironment, proteases cleave and release one half of the functional block. This activates both the targeting antibody and the immunomodulatory function when and where it is needed.
ProTECT™ can change and stop how cancer cells communicate, use, or hide from your immune system to grow.
ProTECT™ is the first conditionally active antibody technology that simultaneously addresses both ends of the therapeutic window, potentially reducing toxicity and increasing antitumor activity.
Unique features of ProTECT™: